EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Recruiting

Phase 2

ExalurenEXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Sponsor:

Eloxx Pharmaceuticals, Inc.

Code:

NCT07523581

Conditions

Alport Syndrome, X-Linked

Alport Syndrome, Autosomal Recessive

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Exaluren

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-12. This information was provided to ClinicalTrials.gov by Eloxx Pharmaceuticals, Inc. on 2026-07-15.